In a population largely naïve to HER2-targeted therapy, pyrotinib in combination with capecitabine was well-tolerated and demonstrates promising antitumor activity in patients with HER2-positive MBC.
No takes yet. Share an insight, caveat, or question.
Li et al. (2019) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: